Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mavorixafor in WHIM Syndrome
NCT03995108Phase 3Completed
- Sponsor
- X4 Pharmaceuticals, Inc.
- Start
- Oct 2019
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 3, randomised, double-blind trial in WHIM syndrome (WHIM) comparing Mavorixafor with Placebo (2 arms). Primary endpoints: Time Above Threshold-Absolute Neutrophil Count of >= 500 Cells/µL over a 24-hour period at 52 weeks and Percentage of Participants With Adverse Events at 56 weeks. Started Oct 2019; status: completed.
02
Drugs
mavorixafor
03
Conditions
WHIM syndrome (WHIM)
Beyond the preview
Go deeper on NCT03995108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03995108.